Download
s12026-021-09234-z.pdf 449,03KB
WeightNameValue
1000 Titel
  • Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment—a population-based cohort study
1000 Autor/in
  1. Kridin, Khalaf |
  2. Schonmann, Yochai |
  3. Solomon, Arie |
  4. Onn, Erez |
  5. Bitan, Dana Tzur |
  6. Weinstein, Orly |
  7. Cohen, Arnon D. |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-10-13
1000 Erschienen in
1000 Quellenangabe
  • 70(1):106-113
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s12026-021-09234-z |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514206/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • The risk of coronavirus disease (COVID-19) infection and its complications among patients with atopic dermatitis (AD) treated by dupilumab is yet to be determined. We aimed to assess the risk of SARS-CoV-2 infection, COVID-19-associated hospitalization, and mortality among patients with AD treated by dupilumab. A population-based cohort study was conducted to compare AD patients treated by dupilumab (n = 238) with those treated by prolonged systemic corticosteroids (≥ 3 months; n = 1,023), phototherapy (n = 461), and azathioprine or mycophenolate mofetil (MMF; n = 194) regarding the incidence of COVID-19 and its complications. The incidence rate of COVID-19, COVID-19-associated hospitalization, and mortality among patients treated by dupilumab was 70.1 (95% CI, 40.5-116.4), 5.0 (95% CI, 0.3-24.7), and 0.0 per 1,000 person-year, respectively. The use of dupilumab was not associated with an increased risk of SARS-CoV-2 infection [adjusted HR for dupilumab vs. prolonged systemic corticosteroids: 1.13 (95% CI, 0.61-2.09); dupilumab vs. phototherapy: 0.80 (95% CI, 0.42-1.53); dupilumab vs. azathioprine/MMF: 1.10 (95% CI, 0.45-2.65)]. Dupilumab was associated with a comparable risk of COVID-19-associated hospitalization [adjusted HR for dupilumab vs. prolonged systemic corticosteroids: 0.35 (95% CI, 0.05-2.71); dupilumab vs. phototherapy: 0.43 (95% CI, 0.05-3.98); dupilumab vs. azathioprine/MMF: 0.25 (95% CI, 0.02-2.74)]. When applicable, the risk of mortality was not elevated in patients with AD treated by dupilumab [HR for dupilumab vs. prolonged systemic corticosteroids: 0.04 (95% CI, 0.00-225.20)]. To conclude, dupilumab does not impose an increased risk of SARS-CoV-2 infection or COVID-19 complications in patients with AD. Dupilumab should be continued and considered as a safe drug for moderate-to-severe AD during the pandemic.
1000 Sacherschließung
gnd 1206347392 COVID-19
lokal Female [MeSH]
lokal Biologics
lokal COVID-19/drug therapy [MeSH]
lokal Aged [MeSH]
lokal Hospitalization [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Antibodies, Monoclonal, Humanized/administration
lokal Incidence [MeSH]
lokal Retrospective Studies [MeSH]
lokal Middle Aged [MeSH]
lokal Risk Factors [MeSH]
lokal COVID-19
lokal AD
lokal Original Article
lokal Survival Rate [MeSH]
lokal COVID-19/mortality [MeSH]
lokal Male [MeSH]
lokal Atopic dermatitis
lokal Disease-Free Survival [MeSH]
lokal Dermatitis, Atopic/drug therapy [MeSH]
lokal SARS-CoV-2 [MeSH]
lokal Dermatitis, Atopic/mortality [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0001-9971-9151|https://frl.publisso.de/adhoc/uri/U2Nob25tYW5uLCBZb2NoYWk=|https://frl.publisso.de/adhoc/uri/U29sb21vbiwgQXJpZQ==|https://frl.publisso.de/adhoc/uri/T25uLCBFcmV6|https://frl.publisso.de/adhoc/uri/Qml0YW4sIERhbmEgVHp1cg==|https://frl.publisso.de/adhoc/uri/V2VpbnN0ZWluLCBPcmx5|https://frl.publisso.de/adhoc/uri/Q29oZW4sIEFybm9uIEQu
1000 Hinweis
  • DeepGreen-ID: cc80657d98aa48d99c7b69afd249131c ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6444270.rdf
1000 Erstellt am 2023-04-27T12:37:14.659+0200
1000 Erstellt von 322
1000 beschreibt frl:6444270
1000 Zuletzt bearbeitet 2023-10-20T12:18:46.913+0200
1000 Objekt bearb. Fri Oct 20 12:18:46 CEST 2023
1000 Vgl. frl:6444270
1000 Oai Id
  1. oai:frl.publisso.de:frl:6444270 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source